Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
BMC Health Serv Res. 2011 Oct 31;11:292. doi: 10.1186/1472-6963-11-292.
The majority of retirement village residents are at risk of medication misadventure. In a recent survey of retirement village residents in Victoria, two-thirds had at least one medication-related risk factor, and hence were eligible to receive a government-subsidised Home Medicines Review (HMR). However, only 6% of eligible residents had received a HMR in the previous 12 months. Reasons for the poor uptake of HMR, and interventions for improving HMR uptake, have been identified and developed with input from stakeholders. The trial will test the effect of Pharmacist-conducted HMR to Address the Risk of Medication-related Events in Retirement Villages (PHARMER) in improving the uptake of HMRs among retirement village residents.
METHODS/DESIGN: This is a multicentre prospective cluster randomised controlled trial. Ten retirement villages in Victoria, Australia will be recruited for this trial. Retirement villages will be selected in consultation with the Residents of Retirement Villages Victoria Inc. (RRVV), based on geographical locations (e.g. northeast or southwest), size and other factors. Residents from selected villages will be recruited with the help of RRVV Resident Liaison Officers using a range of strategies. Randomisation will be by geographical location to minimise contamination. Participating villages and residents will be allocated to either Pharmacist Intervention Group (PIG) or Usual Care Group (UCG). Each group will include five retirement villages and will have at least 77 residents in total. The intervention (PHARMER) comprises educating residents regarding HMR, and using a risk assessment checklist by residents to notify their General Practitioners of their medication risk. Uptake of HMR and medication adherence will be assessed in both PIG and UCG at three and six months using telephone interviews and questionnaires.
This study is the first to develop and test an intervention to improve the uptake of HMR among Australian residents in retirement villages, with a view to decreasing medication risk. A multi-faceted interventional approach will be used as suggested by stakeholders. The trial is expected to be complete by late 2011 and results will be available in 2012.
Australian New Zealand Clinical Trials Registry (ACTRN12611000109909).
大多数退休村居民都存在用药不慎的风险。最近对维多利亚州退休村居民的一项调查显示，三分之二的人至少存在一个与药物相关的风险因素，因此有资格接受政府补贴的家庭药物审查（HMR）。然而，在过去的 12 个月里，只有 6%的符合条件的居民接受了 HMR。已经确定并制定了提高 HMR 利用率的原因和干预措施，并得到了利益相关者的投入。该试验将测试药剂师进行的 HMR 以解决退休村与药物相关的事件风险（PHARMER）在提高退休村居民接受 HMR 方面的效果。
方法/设计：这是一项多中心前瞻性集群随机对照试验。澳大利亚维多利亚州的 10 个退休村将参加这项试验。退休村将根据地理位置（如东北部或西南部）、规模和其他因素与退休村居民维多利亚协会（RRVV）协商选择。将在 RRVV 居民联络官的帮助下，通过一系列策略招募选定村庄的居民。将通过地理位置进行随机分组，以尽量减少污染。参与村庄和居民将被分配到药剂师干预组（PIG）或常规护理组（UCG）。每组将包括五个退休村，总共有至少 77 名居民。干预措施（PHARMER）包括向居民宣传 HMR，并让居民使用风险评估清单向他们的全科医生通知他们的药物风险。将在 PIG 和 UCG 中使用电话访谈和问卷调查在三个月和六个月时评估 HMR 的利用率和药物依从性。
这项研究是第一个开发和测试一种干预措施，以提高澳大利亚退休村居民接受 HMR 的程度，以期降低药物风险。利益相关者建议使用多方面的干预措施。预计该试验将于 2011 年底完成，结果将于 2012 年公布。
澳大利亚新西兰临床试验注册处（ACTRN12611000109909）。
